United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir 700 mg - fosamprenavir calcium tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. the following points should be considered when initiating therapy with fosamprenavir plus ritonavir in protease inhibitor-experienced patients: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to fosamprenavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. limited data are available for use of fosamprenavir in pregnancy. fosamprenavir 700 mg twice daily taken with ritonavir 100 mg twice daily should only be considered in pregnant patients who are already on a stable twice-daily regimen of fosamprenavir/ritonavir 700 mg/100 mg prior to pregnancy, and who are virologically suppressed (hiv-1 rna less than 50 copies per ml) (see clinical considerations and data). there are insufficient human data on the use of fosam

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir calcium tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. the following points should be considered when initiating therapy with fosamprenavir calcium tabletsplus ritonavir in protease inhibitor-experienced patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to fosamprenavir calcium during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data are available for use of fosamprenavir calcium in pregnancy. fosamprenavir calcium 700 mg twice daily taken with ritonavir 100 mg twice daily should only be considered in pregnant patients who are already on a stable twice-daily regimen of fosamprenavir calcium/ritonavir 700 mg/100 mg prior to pregnancy, and who are virologically suppressed (hiv-1 rna less than 50 copies per ml) (see

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir calcium 700 mg - lexiva® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. the following points should be considered when initiating therapy with lexiva plus ritonavir in protease inhibitor-experienced patients: - the protease inhibitor-experienced patient study was not large enough to reach a definitive conclusion that lexiva plus ritonavir and lopinavir plus ritonavir are clinically equivalent [see clinical studies (14.2)] . - once-daily administration of lexiva plus ritonavir is not recommended for adult protease inhibitor-experienced patients or any pediatric patients. lexiva is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome) to any of the components of this product or to amprenavir. - when coadministered with drugs that are highly dependent on cyp3a4 for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatenin

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - fosamprenavir calcium, quantity: 853.2 mg (equivalent: fosamprenavir, qty 700 mg) - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; triacetin; iron oxide red - telzir, in combination with low dose ritonavir, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infected adults, adolescents and children of 6 years and above in combination with other antiretroviral medicinal products. in antiretroviral experienced adults telzir in combination with low dose ritonavir has not been shown to be as effective as lopinavir/ritonavir. no comparative studies have been undertaken in children or adolescents.

United States - English - NLM (National Library of Medicine)

viiv healthcare company - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir 700 mg - lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. the following points should be considered when initiating therapy with lexiva plus ritonavir in protease inhibitor-experienced patients:     •    lexiva is contraindicated when coadministered with the following drugs:               o     alpha 1-adrenoreceptor antagonist: alfuzosin               o     antiarrhythmics: flecainide (with ritonavir), propafenone (with ritonavir)               o     antimycobacterial: rifampin               o     antipsychotic: lurasidone (with ritonavir), pimozide               o     ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine               o     gi motility agent: cisapride               o     herbal product: st. john’s wort (hypericum perforatum )               o     lipid modifying agents: lomitapide, lovastatin, simvastatin               o     non-nucleoside reverse transcriptase inhibitor: delavirdine     

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir 700 mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - fosamprenavir 700 mg

European Union - English - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - hiv infections - antivirals for systemic use - agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (pi) experienced hiv-1 infected adults and children above the age of 4 years. agenerase capsules should normally be administered with low dose ritonavir as a pharmacokinetic enhancer of amprenavir (see sections 4.2 and 4.5). the choice of amprenavir should be based on individual viral resistance testing and treatment history of patients (see section 5.1).the benefit of agenerase boosted with ritonavir has not been demonstrated in pi nave patients (see section 5.1)

European Union - English - EMA (European Medicines Agency)

viiv healthcare bv - fosamprenavir calcium - hiv infections - antivirals for systemic use - telzir in combination with low-dose ritonavir is indicated for the treatment of human-immunodeficiency-virus-type-1-infected adults, adolescents and children of six years and above in combination with other antiretroviral medicinal products. in moderately antiretroviral-experienced adults, telzir in combination with low-dose ritonavir has not been shown to be as effective as lopinavir / ritonavir. no comparative studies have been undertaken in children or adolescents. in heavily pretreated patients, the use of telzir in combination with low-dose ritonavir has not been sufficiently studied. in protease-inhibitor-experienced patients, the choice of telzir should be based on individual viral resistance testing and treatment history.,

Canada - English - Health Canada

viiv healthcare ulc - fosamprenavir (fosamprenavir calcium) - tablet - 700mg - fosamprenavir (fosamprenavir calcium) 700mg - hiv protease inhibitors